Fluvoxamine (Luvox) is the most potent inhibitor of which enzyme?

Fluvoxamine (Luvox) is recognized as the most potent inhibitor of the enzyme CYP1A2. This is significant because CYP1A2 is involved in the metabolism of various psychiatric medications, caffeine, and other substances. When fluvoxamine inhibits this enzyme, it can lead to increased levels of drugs that are substrates of CYP1A2, potentially enhancing their effects or causing side effects.

The implications of this are particularly relevant in clinical settings where fluvoxamine is co-administered with other medications that are metabolized by CYP1A2. It’s essential for healthcare providers to be aware of this interaction in order to adjust dosages appropriately and monitor patients for any adverse reactions or toxicity.

Other enzymes listed, such as CYP2D6, CYP2C19, and CYP3A4, are also involved in drug metabolism, but they are not as significantly affected by fluvoxamine as CYP1A2 is. Understanding these interactions helps clinicians make informed decisions regarding medication management and patient safety.